/

TYRA

Tyra Biosciences, Inc.Open

19.12−0.48 −2.44%USD

NasdaqGS · as of Oct 13, 11:19 ET · 15m delay

Open

19.39

Prev close

19.60

Day range

19.0819.60

52-week range

13.3540.65

Volume

51.75K0.06×

Mkt cap

1.31B

P/E ttm

—

Fwd P/E

-6.90

EPS ttm

-2.39

Div yield

0.00%

Earnings

—

From 52w high

−52.96%

Price Chart

Yahoo Finance · delayed

TYRAOct 13, 2026O 19.39H 19.60L 19.08C 19.12−0.48 (−2.44%)Vol 51.75K

SMA 5024.27
SMA 20030.35

1Y change +41.43% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TYRA Tyra Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.53%
1 month: −13.20%
3 months: −41.84%
6 months: −45.79%
Year to date: −27.27%
1 year: +33.16%

Valuation & ownership

Market cap: 1.31B
Enterprise value: 821.31M
P/E (ttm): —
Forward P/E: -6.90
PEG ratio: —
Price / book: 3.23
Price / sales (ttm): —
EV / EBITDA: -5.14
EPS (ttm): -2.39
EPS (forward): -2.77
Beta (5y monthly): 0.75
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 68.76M
Float: 34.65M
Short % of float: 22.71%
Short ratio (days): 6.85
Held by insiders: 2.43%
Held by institutions: 108.28%
Avg volume (3m): 849.58K
50-day average: 24.53
200-day average: 30.39
52-week change: +33.16%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 32.0
vs 50-day SMA: −21.21%
vs 200-day SMA: −37.00%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.01%
Realised vol (20d, ann.): 49.2%
From 52-week high: −52.96%
From 52-week low: +43.23%

ANR

Analyst Consensus

11 analysts

Consensus

Strong buy

1.27 on a 1 (strong buy) – 5 (sell) scale

Mean target

47.45

+148.18% implied

Low 29.00Median 50.00High 59.00

Recommendation trend

Now14 / 1 / 0
1m ago / 1 /

DES

About Tyra Biosciences, Inc.

Yahoo Finance profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 87
Headquarters: Carlsbad, CA, United States
Website: tyra.bio
Officers: Dr. Todd Harris Ph.D. Co-Founder, CEO, President & Director
Mr. Bhavesh Ashar M.B.A. Chief Operating Officer
Dr. Douglas Warner M.D. Chief Medical Officer
Mr. Daniel Bensen

SEAS

Seasonality · TYRA

2021–2026 · monthly returns

Strongest month Jul +22.19%Weakest month Apr −6.75%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	17.2	8.1	15.0	-9.3	-3.9	-4.4	-0.2	-21.5	-12.6	-12.6			−27.3%
2025	4.0	-19.0	-20.6	10.8	-11.7	5.2	14.2	15.9	10.4	13.2	42.4	16.5	+89.1%
2024	-3.2	49.2	-18.0	4.3	-5.1	-1.4	38.6	2.7	3.3	-29.1	-6.0	-11.4	+0.4%
2023	39.7	24.4	21.7	-11.8	2.1	17.7	-13.0	2.8	-9.6	-15.8	0.9	18.3	+82.2%
2022	-6.8	-9.6	-9.7	-30.2	-8.6	4.7	49.0	-37.9	33.0	-21.3	1.3	8.4	−46.0%
2021										27.3	12.1	-43.9	−20.0%

INSD

Insider Activity · TYRA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 8, 2026	Verjee RehanDirector	Purchase at price 20.58 per share.	971	$20.00K
May 4, 2026	Harris Todd JamesChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	79K	—
May 4, 2026	Fuhrman Alan CpaChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	20K	—
May 4, 2026	Ashar BhaveshChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	15K	—
May 4, 2026	Warner Douglas JOfficer	Stock Award(Grant) at price 0.00 per share.	25K	—
May 4, 2026	Rueb YuliyaOfficer	Stock Award(Grant) at price 0.00 per share.	8.3K	—
Mar 25, 2026	Kaplan GillaDirector	Conversion of Exercise of derivative security at price 2.25 per share.	67.5K	$151.80K
Mar 24, 2026	Kaplan GillaDirector	Sale at price 36.97 per share.	14.3K	$528.51K
Mar 12, 2026	Harris Todd JamesChief Executive Officer	Stock Award(Grant) at price 36.22 per share.	1.5K	$52.99K
Mar 12, 2026	Fuhrman Alan CpaChief Financial Officer	Stock Award(Grant) at price 36.22 per share.	1.4K	$49.84K
Feb 11, 2026	Bensen DanielOfficer	Sale at price 31.50 - 33.37 per share.	8K	$262.96K
Jan 11, 2026	Bensen DanielOfficer	Sale at price 28.44 - 29.08 per share.	8K	$228.19K
Dec 18, 2025	More Robert JDirector	Sale at price 25.00 per share.	10K	$250.00K
Dec 11, 2025	Bensen DanielOfficer	Sale at price 22.64 per share.	8K	$181.16K
Nov 20, 2025	More Robert JDirector	Sale at price 20.25 per share.	246.9K	$5.00M
Nov 18, 2025	Bensen DanielChief Operating Officer	Sale at price 16.07 - 16.32 per share.	125.6K	$2.03M
Nov 16, 2025	Bensen DanielChief Operating Officer	Sale at price 16.00 - 17.07 per share.	131.4K	$2.11M
Sep 14, 2025	Fuhrman Alan CpaChief Financial Officer	Stock Award(Grant) at price 12.31 per share.	701	$8.63K
Jun 17, 2025	Kaplan GillaDirector	Sale at price 9.78 - 10.35 per share.	9.6K	$93.70K
Jun 15, 2025	Kaplan GillaDirector	Sale at price 10.31 - 10.38 per share.	51.8K	$534.56K

TYRA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TYRA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Tyra Biosciences, Inc.

Seasonality · TYRA

Insider Activity · TYRA

Congress Trades · TYRA

Investors Holding TYRA

Investors Holding TYRA

Congress Trades · TYRA

Seasonality · TYRA

Insider Activity · TYRA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Tyra Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News